1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Corbus Cystic Fibrosis Data May Justify Longer, Larger Study

 
• By Mandy Jackson

Safety was the primary endpoint in a Phase II study for the inflammation-targeting drug anabasum, but Corbus believes an efficacy signal viewed outside of the secondary endpoints justifies further development.

Cystic fibrosis word cloud

Corbus Pharmaceuticals Holdings Inc. searched for efficacy in a Phase II cystic fibrosis study for its only clinical drug candidate, anabasum (JBT-101; resunab), but the signal highlighted by the company was found in a data point outside of the trial's pre-defined endpoints.

The clinical trial's primary endpoint sought acceptable safety and tolerability for the endocannabinoid-mimetic drug, which preferentially binds to the cannabinoid-2 (CB2) receptor on activated immune cells and fibroblasts; it resolves...

More from Clinical Trials

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

More from R&D

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.